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Epidermal growth factor receptor (EGFR) is expressed,
albeit at low or intermediate levels, in human melanomas
at the different stages of tumor progression. Coexpression
of EGFR with its ligand TGFa indicates their role in
paracrine and autocrine growth regulation of melanomas.
As it was previously observed for several types of cancer,
specific inhibitors of EGFR-mediated signaling may
reduce antiapoptotic properties of cancer cells and
sensitize them to cytotoxic drugs. We recently reported
that arsenite, particularly in combination with inhibitors
of the PI3K-AKT and mitogen-activated protein kinase
(MAPK) kinase (MEK)-extracellular signal-regulated
kinase (ERK) pathways, induces high levels of apoptosis
in different melanomas. Since EGFR signaling operates
via activation of the PI3K-AKT and MEK-ERK path-
ways, we suggested that the combination of arsenite and
EGFR inhibitors might also effectively induce apoptosis in
melanoma. Here, we demonstrate that a moderate
concentration of arsenite (5–10 lM) indeed upregulates
apoptosis induced by EGFR inhibitors in EGFR-positive
melanomas. In contrast, induction of apoptosis in
melanomas with negligible surface expression of EGFR
or with defective EGFR signaling requires direct suppres-
sion of the PI3K-AKT and MAPK pathways by specific
pharmacological inhibitors in the presence of arsenite.
Under these conditions, metastatic melanoma cell lines
undergo TNF-related apoptosis-inducing ligand (TRAIL)-
and tumor necrosis factor alpha (TNFa)-mediated apop-
tosis. Taken together, these data provide additional
approaches in sensitizing melanomas to the cytotoxic
effects of specific inhibitors of survival pathways.
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Introduction
Epidermal growth factor receptor signaling has become
an important target in anticancer drug development due
to its ability to control tumor cell proliferation and to
suppress apoptosis (Yarden and Sliwkowski, 2001).
Extensive efforts to develop epidermal growth factor
receptor (EGFR) inhibitors for anticancer therapy
(Levitzki and Gazit, 1995; Wakeling et al., 1996; Dancey
and Sausville, 2003; Gschwind et al., 2004) finally led to
approval of one of the small reversible inhibitors,
gefitinib (Iressa, AstraZeneca), for non-small-cell lung
cancer treatment and of an inhibitory anti-EGFR
monoclonal antibody, IMC-C225 (Erbitux, ImClone
Systems), for metastatic colorectal cancer treatment.
Activation of the EGFR pathway in cancer cells is based
on several distinct mechanisms, such as amplification
and/or overexpression of the EGFR gene, increased
production of ligands, EGF or TGFa, decreased
receptor turnover, and the presence of altered forms of
receptors due to specific activating mutations or
profound gene rearrangement. Effects of EGFR signal-
ing on cell proliferation and survival are mediated by the
mitogen-activated protein kinase (MAPK), PI3K-AKT
and STAT pathways (Schlessinger, 2000; Sibilia et al.,
2000; Yarden and Sliwkowski, 2001; Gschwind et al.,
2004). Despite a ubiquitous low-level expression of
EGFR in normal cells, inactivation of the EGFR gene in
mice has minimal effects on development and survival
(Threadgill et al., 1995), indicating that pharmacological
inhibition of EGFR signaling should have relatively
minor effects on normal cells. The results of clinical
trials for non-small-cell lung cancer with the EGFR
inhibitor gefitinib were relatively modest, showing
objective tumor response rates of 10–18% (Blackledge
and Averbuch, 2004; Dancey, 2004). However, the
identification of genetic changes in the EGFR kinase
domain that can predict tumor response to gefitinib was
described in two recent publications (Lynch et al., 2004;
Paez et al., 2004), resolving the problem of when
gefitinib-based monotherapy will be effective for non-
small-cell lung cancer treatment. Combined chemother-
apy to treat different forms of cancer, as a rule, is much
more effective than monotherapy. However, the addi-
tion of gefitinib to traditional chemotherapy failed to
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induce significant responses (Giaccone et al., 2004),
indicating the importance of finding proper combina-
tions of EGFR inhibitor with modulators of other
signaling pathways in the cell.
Melanoma is largely curable at early stages of cancer
development; however, there are no adequate treatments
for locally advanced or metastatic stages of this disease
(Perlis and Herlyn, 2004). Therefore, it is very important
to develop novel agents, especially in different combina-
tions, that are both effective and low in toxicity for
melanoma treatment. In contrast to some other tumors,
melanomas express EGFR only at low or intermediate
levels while other types of growth factor receptors, such
as FGFR1 and IGF-1R, and their correspondent
growth factors are also involved in the paracrine and
autocrine control of melanoma cell proliferation (Hala-
ban, 1996; Lazar-Molnar et al., 2000). In the present
study, we have addressed the question with regard to
effects of suppression of EGFR signaling on melanoma
survival. Previously, we reported that arsenite in
combination with inhibitors of the PI3K-AKT and
mitogen-activated protein kinase (MEK)-extracellular
signal-regulated kinase (ERK) pathways induces high
levels of apoptosis in different melanomas (Ivanov and
Hei, 2004). Since EGFR signaling operates via activa-
tion of the PI3K-AKT and MEK-ERK pathways
(Yarden and Sliwkowski, 2001), we suggested that the
combination of arsenite and EGFR inhibitors would
also be an effective inducer of apoptosis in melanoma.
Here, we demonstrate that a moderate concentration of
arsenite (5–10 mM) induces an additive or synergistic
upregulation of apoptosis stimulated by EGFR inhibi-
tors in EGFR-positive melanomas. In contrast, apop-
tosis induction in melanomas with negligible surface
expression of EGFR requires direct suppression of the
PI3K-AKT and MAPK pathways by specific pharma-
cological inhibitors in the presence of arsenite. Under
these conditions, metastatic melanoma cells may under-
go TNF-related apoptosis-inducing ligand (TRAIL)- or
tumor necrosis factor alpha (TNFa)-mediated apopto-
sis. These data provide additional approaches to
increase apoptotic responses of melanomas to cytotoxic
effects of specific inhibitors of survival pathways.
Results
EGFR surface expression in human melanomas and
sensitivity of cancer cells to EGFR inhibitors
The EGFR surface expression has been determined
using monoclonal anti-EGFR antibody and flow
cytometry in both human melanocytes and melanoma
cell lines at different stages of tumor progression
(Figure 1a). Melanocytes possess low, almost negligible
surface levels of EGFR (data not shown). Radial growth
phase WM35 and metastatic HHMSX, FEMX, LOX
and OM431 melanoma cells were also characterized by
negligible surface expression of EGFR. On the other
hand, two early melanoma cell lines, SBcl2 (radial
growth phase), WM793 (vertical growth phase), and
WM9 metastastic melanoma demonstrated average
levels of surface expression of EGFR; LU1205 meta-
static melanoma cells possess a low surface expression of
EGFR (Figure 1a). These data indicate an absence of a
direct correlation between surface EGFR expression
and the stage of melanoma development. Furthermore,
high levels of surface EGFR expression may not directly
correlate to the efficiency of EGFR signaling due to the
possibility of inactivating mutations in the EGFR gene
(Lynch et al., 2004). The WM793 and WM9 melanoma
cells were chosen for treatment with increased doses of
AG1478, a highly specific inhibitor of EGFR signaling
(Levitzki and Gazit, 1995). AG1478 (20 mM) induced
reasonably high levels of apoptosis 48 h after treatment
of these cells (Figure 1b); PD153035, another inhibitor
of EGFR signaling, demonstrated the similar effects
(data not shown). Two EGFR inhibitors (20 mM) have
been applied for treatment of human melanocytes and
additional melanoma cell lines. These concentrations of
inhibitors are equivalent to doses, which have been used
recently in clinical trails of gefitinib (Iressa, AstraZene-
ca) for non-small-cell lung cancer treatment (Levitzki
and Gazit, 1995; Wakeling et al., 1996; Dancey and
Sausville, 2003; Gschwind et al., 2004). Besides WM793
and WM9, only SBcl2 melanoma cells with intermediate
levels of surface expression of EGFR developed high
levels of apoptosis following treatment with inhibitors
(Figure 1c).
Arsenite increases apoptosis induced by EGFR inhibitors
We previously observed that a moderate concentration
of arsenite (5–10 mM) may effectively induce apoptosis in
melanomas, particularly in combination with inhibitors
of the MEK-ERK and PI3K-AKT pathways (Ivanov
and Hei, 2004). We suggested that the combined
treatment of arsenite and EGFR inhibitor should also
be an effective inducer of apoptosis in melanoma,
because EGFR-mediated signaling operates via MEK-
ERK and PI3K-AKT pathways (Yarden and Sliwkows-
ki, 2001). Indeed, AG1478 (20 mM) in concert with
arsenite (10 mM) demonstrated additive effects in the
induction of apoptosis of WM793 cells 24 and 48 h after
treatment (Figure 2a). It is interesting to note that the
effects of AG1478 on apoptosis were quite similar to the
effects of LY294002, an inhibitor of the PI3K-AKT
pathway (Figure 2b). Indeed, Western blot analysis of
the total protein of WM793 cells indicated a suppression
of EGFR phosphorylation and a substantial inhibition
of phospho-AKT levels following treatment with
AG1478 or combination of AG1478 and arsenite.
Simultaneously, EGFR inhibitor AG1478 did not affect
basal or arsenite-induced phospho-ERK levels, reveal-
ing that the MEK-ERK pathway was not activated by
EGFR signaling in WM793 melanoma cells. Heme
oxygenase-1 (HO-1) induction was chosen as a hallmark
of oxidative stress stimulated by arsenite; AG1478
effectively blocked HO-1 induction by arsenite, indicat-
ing possible involvement of the PI3K-AKT pathway in
this regulation (Figure 2c). So, from two main signaling
pathways, MEK-ERK and PI3K-AKT usually activated
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by EGFR in different cell systems, only the PI3K-AKT
pathway was under the control of EGFR signaling in
early melanoma WM793 cells. It correlates with the
presence of BRAF activating mutation T1796A
(V599E), which makes the downstream MEK-ERK
cascade partially independent of GFR stimulation, in
many melanoma lines including WM793 (Dong et al.,
2003; Satyamoorthy et al., 2003). Our data also indicate
that alternative FGFR1-, IGF-1R- or c-Met-mediated
signaling may be involved in the regulation of the MEK-
ERK cascade in melanomas (Satyamoorthy et al., 2003).
The PI3K-AKT pathway affects general cell survival
and proliferation via control of protein levels and
activities of several transcription factors and correspon-
dent target genes, as well as via regulation of the mTOR
kinase that is the central controller of general protein
synthesis (Bjornsti and Houghton, 2004; Hanada et al.,
2004). Furthermore, the PI3K-AKT pathway has some
specific antiapoptotic functions, such as an inactivation
of caspase-9 and proapoptotic protein Bad (Kandel and
Hay, 1999). We used rapamycin (100 nM) for specific
inhibition of mTOR (Figure 2b). Rapamycin did not
promote the effects of arsenite-induced apoptosis,
indicating that the AKT-mTOR pathway was not
critically involved in the regulation of this type of
apoptosis in WM793 cells. On the other hand, herbi-
mycin, a general inhibitor of protein tyrosine kinases,
induced apoptosis of WM793 melanoma cells and
increased arsenite-induced apoptosis of these cells high-
lighting the role of protein tyrosine kinases in general
cell survival (Figure 2b). One of the prominent
antiapoptotic actions of arsenite, suppression of nuclear
factor kappa B (NF-kB) activity and NF-kB-dependent
transcription (Kapahi et al., 2000; Ivanov and Hei,
2004), which was observed after treatment WM793 cells
by arsenite alone or in concert with AG1478 (data not
shown), may be responsible for enhancing AG1478-
induced apoptosis.
Caspase-3-mediated cleavage of PARP, an important
feature of apoptosis, was evident 18 h after treatment
with AG1478, PD153035, arsenite and combinations of
inhibitors with arsenite (Figure 2d). To further investi-
gate the role of caspases in apoptosis induced by EGFR
inhibitors, we used N-acetyl-Ile-Glu-Thr-Asp-CHO
(aldehyde) (Ac-IETD-CHO) (an inhibitor of caspase-8
and -6), N-acetyl-Leu-Glu-His-Asp-CHO (aldehyde)
Figure 1 EGFR inhibitors induce apoptosis in human melanomas. (a) Cell surface EGFR expression on melanocytes and human
melanomas was determined by staining with PE-conjugated anti-human EGFR monoclonal antibody and flow cytometry. Filled
histograms represent nonspecific staining with mouse Ig-PE. Mean fluorescent intensity (MFI) is indicated. WM35 cells, as well as
HHMSX, FEMX, LOX and OM431, are EGFR negative. (b) Dose–response induction of apoptosis by AG1478 in two melanoma
lines, WM793 and WM9. (c) Cell-cycle apoptosis analysis of human melanocytes and melanoma cells treated with AG1478 or
PD153035 (20 mM) for 24 h. Cells were stained with PI and percentage of cells with hypodiploid content of DNA was determined by
flow cytometry
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(Ac-LEHD-CHO) (an inhibitor of caspase-9) and
zVAD-fmk (a general caspase inhibitor). Both caspase-
8 and -9 inhibitors notably suppressed apoptosis
induced by AG1478, but were less effective for suppres-
sion of PD153035-induced cell death; zVAD-fmk treat-
ment was an effective suppressor for death induction by
AG1478 or PD153035 (Figure 2e).
We further elucidated the effects of arsenite on
AG1478-induced apoptosis using two additional
EGFR-positive melanomas, SBcl2 and WM9
(Figure 3). For both lines, EGFR inhibitors AG1478
(20 mM) or PD153035 (20 mM) and PI3K-AKT inhibitor
LY294002 (50 mM) induced apoptosis and dramatically
enhanced apoptotic effects of arsenite (Figure 3a and b).
Figure 2 Arsenite increases the apoptotic response of WM793 melanoma (vertical growth phase) cells to the EGFR inhibitor. (a)
Additive effects of AG1478 (20mM) and arsenite (10mM) for the induction of apoptosis of WM793 melanoma cells 24 and 48 h after
treatment. (b) Effects of LY294002 (50 mM), rapamycin (100 nM) or herbimycin (10 and 20 mM) on arsenite-induced apoptosis. Cell-
cycle apoptosis analysis was 24 h after treatment performed using flow cytometry. (c) Western blot analysis of total and phospho-
EGFR, phospho-ERK and phospho-AKT levels following treatment with AG1478 (20mM), arsenite (10mM) or their combination.
Induction of HO-1 was used as a demonstration of arsenite-induced oxidative stress. b-Actin served as an internal standard. (d) PARP
cleavage was determined by Western blot analysis 18 h after treatment with AG1478 (20 mM), PD153035 (20 mM), arsenite (10 mM) and
indicated combinations of inhibitors with arsenite. (e) Effects of caspase inhibitors, Ac-IETD-CHO (50mM), Ac-LEHD-CHO (50mM)
and zVAD-fmk (50mM), on induction of apoptosis of WM793 cells by AG1478 or PD153035 (20mM) treatment
EGFR inhibitors and arsenite upregulated apoptosis
VN Ivanov and TK Hei
619
Oncogene
It was well correlated with the downregulation of EGFR
phosphorylation and a decrease in basal phospho-AKT
activity following AG1478 (20 mM) treatment
(Figure 4a). No negative effects of AG1478 on basal
or arsenite-induced phospho-ERK levels have been
observed. Arsenite-induced HO-1 activity was substan-
tially suppressed in the presence of AG1478 (Figure 4a).
As expected, arsenite alone or in the combination with
AG1478 downregulated NF-kB activity and NF-kB-
dependent transcription (data not shown) providing
conditions favorable to enhancement of apoptosis.
Apoptotic abilities of AG1478, PD153035 and arsenite
in WM9 metastatic melanoma that finally target
caspase-3 were additionally confirmed by the specific
caspase-3-dependent cleavage of PARP 18 h after
treatment (Figure 4b). To further verify the role of
AKT as a target of suppression by EGFR inhibitors, we
used previously established WM9-AKTmyr cells (Ivanov
et al., 2002) with high levels of permanently active
phospho-AKT and control WM9-puro cells (Figure 4c).
WM9-AKTmyr cells were substantially more resistant to
apoptotic effects of LY294002 and AG1478 than control
cells (Figure 4d).
Suppression of PI3K-AKT and MEK-ERK pathways
partially reproduces the effects of GFR inhibitors
LU1205 metastatic melanoma cells have low levels of
surface EGFR (Figure 1a) and are relatively resistant to
arsenite treatment. As expected in this case, EGFR
inhibitors, AG1478 (Figure 5a) and PD153035 (not
shown), induced only slight apoptotic effects and did
not upregulate arsenite-induced apoptosis in LU1205
melanoma cells. By contrast, herbimycin, a general
protein tyrosine kinase inhibitor, was very effective for
increasing arsenite-induced apoptosis in LU1205 cells
(Figure 5a), demonstrating a probable role of alternative
growth factor receptor pathways in the regulation of cell
survival in case of deficiency of EGFR signaling. Since
inhibition of both PI3K-AKT and MEK-ERK path-
ways may partially mimic the downstream effects of
growth factor receptor inhibition, we treated LU1205
cells with LY294002 (50 mM) and PD98059 (50 mM) with
or without arsenite (Figure 5a). We previously observed
(Ivanov and Hei, 2004) that such treatments induced
high levels of apoptosis in LU1205 cells. As expected,
the combination of LY294002 with arsenite was less
Figure 3 Arsenite synergizes with EGFR inhibitors for the
induction of apoptosis in the sBCL2 melanoma (horizontal growth
phase) and WM9 metastatic melanoma cells. (a and b) Synergistic
effects of AG1478 (20 mM), PD153035 (20 mM), LY294002 (50mM)
and arsenite (10mM) for the induction of apoptosis of sBCL2 and
WM9 melanoma cells 24 h after treatment. Cell-cycle apoptosis
analysis was performed using flow cytometry
Figure 4 Regulation of EGFR-mediated signaling in WM9
melanoma cells. (a) Western blot analysis of total and phospho-
EGFR, phospho-ERK, phospho-p38 and phospho-AKT levels
following AG1478 (20mM), arsenite (10mM) or combined treat-
ment. Induction of HO-1 was used as an indication of arsenite-
induced oxidative stress. b-Actin levels were used as an internal
control. (b) PARP cleavage was determined by Western blot
analysis 18 h after treatment with AG1478 (20mM), PD153035
(20 mM) or arsenite (10mM). (c and d) Overexpression of AKTmyr
protects WM9 melanoma cells from apoptosis induced by
LY294002 (50 mM) or AG1478 (20mM)
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effective than the combination of LY294002, PD98059
and arsenite (data not shown).
Staining LU1205 cells by Annexin-V–FITC and
propidium iodide (PI) with subsequent flow cytometry
revealed initial apoptotic and secondary necrotic events
6 h after arsenite treatment in the presence of inhibitors
(data not shown). Western blot analysis indicated
suppression of phospho-AKT and phospho-ERK2
activities following treatment with the combination of
specific inhibitors, while electrophoretic mobility shift
assay (EMSA) demonstrated a downregulation of NF-
kB DNA-binding activity (for both bands p65-p50 and
p50-p50) (Figure 5b) and NF-kB-dependent transcrip-
tion (data not shown) in the presence of arsenite. Since
LU1205 cells produce TRAIL and TNFa and have
surface expression of tumor necrosis factor receptor
(TNFR)1, DR4 and DR5 death receptors (Griffith et al.,
1998; Ivanov and Ronai, 1999), a decrease in the basal
NF-kB activity by arsenite, a decrease in AKT activity
by LY294002 and a decrease in ERK activity by
PD98059 may sensitize these cells to TRAIL- or
TNFa-mediated cell suicide (Chen et al., 2001; Franco
et al., 2001; Zhang et al., 2003b). Indeed, pretreatment
with anti-TRAIL or, to a lesser extent, with anti-TNFa
antibodies partially suppressed apoptosis that was
induced by arsenite in combination with LY294002
and PD98059 (Figure 5c). Hence, for melanoma cells
with low or negligible levels of surface EGFR, it was
possible to induce efficient levels of apoptosis by direct
inhibition of downstream PI3K-AKT and MEK-ERK
signaling pathways in the presence of arsenite.
HO-1 activity as a target of EGFR signaling
What are some of the target genes, whose expressions
are dependent on both the EGFR- and arsenite-
mediated signaling? Determination of arsenite-affected
gene expression in several cell systems using microarrays
revealed a dramatic upregulation of HO-1 following
arsenite treatment (Liu et al., 2001a; Yih et al., 2002;
Rea et al., 2003; Zheng et al., 2003). Induction of HO-1
is the hallmark feature of oxidative stress (Durante,
2003). Arsenite efficiently induced HO-1 in melanomas
6 h after treatment with maximal levels at a dose 10–
20 mM (Figure 6a). The role of AP-1/activating tran-
scription factor 2 (ATF2) transcription factors in the
regulation of HO-1 gene expression has been well
established (Alam and Den, 1992; Lee et al., 2000;
Gong et al., 2002). AP-1 exists in multiple homo or
hetero combinations of Jun–Jun, Jun–Fos and Jun–
ATF2 proteins, which may be targets of different
signaling pathways (Shaulian and Karin, 2002). A
probable function of HIF-1 in the transcriptional
activation of HO-1 was also described (Lee et al.,
1997). SB203580 (an MAPK p38-ATF2 inhibitor) and
most effectively LY294002 (a PI3K-AKT inhibitor)
downregulate the HO-1 induction in both WM793 and
LU1205 melanoma cells. PD98059 (an MEK-ERK-
Elk1-cFos inhibitor) was partially effective only in
LU1205 cells. SP600125 (Jun N-terminal kinase (JNK)’s
inhibitor) did not notably affect HO-1 protein levels in
Figure 5 Combined treatment with LY294002, PD98059 and
arsenite induces TRAIL-mediated apoptosis in LU1205 melanoma
cells. (a) Herbimycin (20 mM), but not AG1478 (20mM), enhances
arsenite-induced apoptosis in LU1205 melanoma cells; combina-
tion of LY294002 (50mM) and PD98059 (50mM) also upregulates
arsenite-induced apoptosis. Cell-cycle apoptosis analysis was
performed using flow cytometry of PI-stained cells. (b) Western
blot analysis of total and phospho-AKT, phospho-ERK and
TRAIL levels following LY294002 (50 mM) and PD98059 (50mM)
treatment in the presence or absence of arsenite (10mM). NF-kB
DNA-binding activity of nuclear proteins was determined by
EMSA. Two DNA-binding complexes are indicated NF-kB p65-
p50 and (p50)2. (c) Apoptosis analysis of LU1205 cells treated by
LY294002 (50mM)þPD98059 (50mM) with or without arsenite
(10mM) in the presence of nonspecific IgG, inhibitory anti-TRAIL
or anti-TNFa mAb (5 mg/ml). FACS analysis was performed with
PI-stained melanoma cells. A percentage of apoptotic cells 24 h
after treatment is indicated
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indicated melanoma lines (Figure 6a). Taken together,
these data supported the role of AP-1/ATF2-dependent
regulation of HO-1 expression (via MAPK p38 and ERK)
in melanomas. Targets of PI3K-AKT signaling for the
HO-1 expression are not completely identified. Probable
targets are transcription factors NRF2 and HIF-1, which
controls the HO-1 gene transcription. The stability of
NRF2 and HIF-1 proteins is dependent on PI3K-AKT
signaling (Jiang et al., 2001; Alam and Cook, 2003;
Martin et al., 2004). If inhibitors of EGFR signaling
downregulate the PI3K-AKT pathway, they also should
suppress HO-1 induction by arsenite. Indeed, we observed
an effective suppression of arsenite-induced HO-1 expres-
sion in the EGFR-positive WM793 melanoma cells by
AG1478 and the absence of suppression for the EGFR-
negative FEMX cells (Figure 6b and c).
HO-1 is known to possess numerous antioxidative
stress functions, including interference and suppression
of TNF- and FasL-mediated apoptosis (Brouard et al.,
2002; Zhang et al., 2003a). Direct suppression of HO-1
by introduction of its pharmacological inhibitor, Zn-
containing protoporphyrin IX (PP IX (Zn2þ )) (50 mM),
notably accelerated arsenite-induced apoptosis of
WM793 melanoma cells and had a certain, but relatively
mild increase in apoptosis for LU1205 cells (data not
shown). Positive regulation of expression of antiapop-
totic protein HO-1 by PI3K-AKT and MEK-ERK
pathways or by EGFR signaling allows connecting the
upregulation of arsenite-induced apoptosis after
LY294002, PD98059 or AG1478 cotreatment (see
Figures 2 and 3), to a certain extent, with suppression
of the HO-1 expression.
It is interesting to note that downregulation of
arsenite-induced HO-1 protein levels in cancer cells by
EGFR inhibitors may serve as an easily performed
additional test in the determination of the physiologi-
cally active state of EGFR signaling in these cells (as an
alternative to the determination of EGFR phosphoryla-
tion). The absence of the surface EGFR expression or
mutations of EGFR that disturb EGFR-mediated
signaling may suppress the effects of EGFR inhibitors
on HO-1 activity, as we observed for FEMX melanoma
cells (Figure 6b and c).
Discussion
Apoptosis is one of the key regulatory mechanisms in
the development of multicellular organism and in the
regulation of its general homeostasis, and also in the
initiation and progression of degenerative diseases.
Apoptosis serves as a defensive mechanism to remove
potentially dangerous cells such as primary tumor cells
and virus-infected cells. However, most if not all
metastatic cancer cells have serious defects in the control
of apoptosis providing cancer cells the ability to resist
death (Evan and Vousden, 2001; Johnstone et al., 2002;
Kitada et al., 2002). Two fundamental signaling path-
ways, Ras-Raf-MEK-ERK-(Elk1, activator protein-1
(AP-1)) and PI3K-AKT-(FKHD, mTOR), which are
initiated by the interactions of growth factor receptors
with cognate growth factors, are involved in the
regulation of cell proliferation and general cell survival
(Figure 7). Components of these two pathways are
frequent targets for gene mutations, which may change
their inducible status to a permanently active state. For
example, RAS and BRAF genes together have activating
mutations in almost 80% of all melanomas (Davies
et al., 2002; Tuveson et al., 2003; Reifenberger et al.,
2004). The EGFR gene by itself is also very often
mutated in different tumors (Lynch et al., 2004). The
NF-kB signaling pathway TNFR-TRAF2-IKK-
IkB*NF-kB-(NF-kB) (Figure 7), which balances cell
survival and proapoptotic functions, is also often
overactivated in different tumors as a result of
epigenetic or genetic alterations (Karin et al., 2002,
2004; Orlowski and Baldwin, 2002; Lin and Karin, 2003;
Chen and Greene, 2004).
We recently investigated apoptotic activity of arsenite
in human melanomas (Ivanov and Hei, 2004), which is
based on two main aspects of arsenite function in the
cell: (1) arsenite acts as a sulfhydryl reagent, which binds
to free thiol (–SH) group of enzymes and inhibits their
functions (Snow, 1992) and (2) arsenite induces strong
production of reactive oxygen species (ROS) with
Figure 6 Regulation of HO-1 activity by arsenite in melanoma
cells: effects of inhibition of signal transduction pathways. (a)
Effects of LY294002 (50 mM), PD98059 (50 mM), SP600125 (10mM)
and SB203580 (10mM) on arsenite (10 mM)-induced HO-1 protein
levels in melanoma cells. (b) Surface EGFR levels were determined
by flow cytometry of stained FEMX and WM793 cells. Filled
histogram represents nonspecific staining with mouse Ig-PE. (c)
Western blot analysis of HO-1 levels from WM793 and FEMX
cells following treatment with AG1478 (20 mM), arsenite (10mM) or
their combination
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subsequent development of oxidative stress, which
affects multiple targets in the cell (Hei et al., 1998; Liu
et al., 2001b; Li et al., 2002). There are two important
targets of enzymatic inhibition by arsenite: (1) inhibitor
nuclear factor kappa B-kinase b (IKKb) (Kapahi et al.,
2000; Roussel and Barchowsky, 2000; Hershko et al.,
2002), which results in the suppression of NF-kB
transcription factor activation followed by the dramatic
change of the anti- and proapoptotic functions of the
cells (Karin and Lin, 2002; Amit and Ben-Neriah, 2003;
Mathas et al., 2003) and (2) JAK2 tyrosine kinase,
which results in the inhibition of tyrosine phosphoryla-
tion and functional activation of Stat3, which controls
numerous survival functions of cells (Darnell, 2002;
Levy and Darnell, 2002; Hayashi et al., 2003; Cheng
et al., 2004). As a result of oxidative stress, stress-
induced kinase pathways (MKK6-MAPK p38, MKK4/
7-JNK and MEK-ERK1/2) simultaneously activate and
upregulate the AP-1 (Jun–Fos, Jun–ATF2) transcrip-
tion factors and induce AP-1-dependent gene expression
(Cavigelli et al., 1996; Chen et al., 1998; Ludwig et al.,
1998; Bode and Dong, 2002). On the one hand,
arsenite suppresses general cell survival via inhibition
of NF-kB and Stat3, and on the other, it stimulates
MAP kinases and some antiapoptotic functions. To
enhance proapoptotic events, it would be necessary to
suppress the MAPK and PI3K-AKT pathways in
concert with arsenite treatment (Figure 7). We present
here data that show the additive or synergistic effects of
EGFR inhibitors and arsenite on apoptosis in EGFR-
positive melanomas. In these melanomas, EGFR
inhibitors suppressed the PI3K-AKT pathway, while
the MEK-ERK pathway was independent of their
actions. This obviously indicates that other GFRs (such
as FGFR1, IGF-1R and c-Met) are involved in the
regulation of MEK-ERK signaling in melanomas
(Satyamoorthy et al., 2003; von Willebrand et al.,
2003). Furthermore, BRAF T1796A (V599E) activating
mutation, which has been found in WM793, WM9,
LU1205, OM431 and LOX melanomas (but not in
SBcl2, WM35 or FEMX) upregulates basal levels of
ERK activity (Dong et al., 2003; Krasilnikov et al.,
2003; Satyamoorthy et al., 2003). The combination of
LY294002 (an inhibitor of PI3K-AKT), U0126 (an
inhibitor of MEK1/2-ERK) and arsenite (an inhibitor of
IKKb and JAK2), which affects the downstream targets
of GFR and NF-kB signaling, was extremely effective
for the induction of apoptosis in all tested melanomas,
as well as in the prostate adenocarcinomas (VN Ivanov
and TK Hei, unpublished observations).
Figure 7 Kinase targets and inhibitors. A schematic illustration of the principal signaling pathways that are affected by the inhibitors,
which are described in this paper. Protein tyrosine kinase activity of EGFR is inhibited with AG1478 or PD153035. Downstream
events of EGFR-mediated signaling include a formation of multisubunit scaffold complex with the activation of the Ras-Raf-MEK-
ERK pathway. PD98059 and U0126 are specific inhibitors of MEK1/2. The PI3K-AKT pathway that is initiated at the active EGFR
can be suppressed with pharmacological inhibitor LY294002 or with the endogenous inhibitor PTEN. The MEK-ERK and PI3K-
AKT pathways activate the specific sets of transcription factors, which are involved in the antiapoptotic and cell-cycle gene expression.
AKT also regulates general protein translation via mTOR kinase, which is sensitive to rapamycin. The TNFR-mediated signaling
induces via adaptor proteins IKK activity followed by phosphorylation and proteasome-dependent degradation of IkB, and release
and nuclear translocation of NF-kB, which regulates the expression of many different genes, including antiapoptotic genes.
Simultaneously, the TNFR-mediated signaling may activate caspase-8/caspase-3 proapoptotic pathway; at normal conditions,
however, this pathway is suppressed by the NF-kB-dependent antiapoptotic proteins. Arsenite upregulates the MAPK pathways, but
eventually suppresses IKK-NF-kB activation affecting a balance between cell survival and apoptosis
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There is an obvious mechanistic analogy in the
general arrangement of pro- and antiapoptotic signaling
between melanomas and prostate adenocarcinomas. In
this respect, androgen-dependent LNCaP cells with low
basal NF-kB activity and high sensitivity to TNFa- or
arsenite-induced apoptosis are similar to early WM793
melanoma cells. On the other hand, highly aggressive
androgen-independent DU145 prostate cancer cells
with a high basal NF-kB activity and resistance to both
TNFa- or arsenite-induced apoptosis are quite similar to
metastatic melanoma LU1205. For both cell systems,
downregulation of the basal NF-kB activities by different
agents may induce TNFa- and TRAIL-mediated apop-
tosis (Huerta-Yepez et al., 2004). Surprisingly, in spite of
the high surface expression of EGFR in PC3 and DU145
prostate cancer cells, inhibitors of EGFR (alone or in
concert with arsenite) induced only modest levels of
apoptosis (VN Ivanov and TK Hei, unpublished observa-
tions). This was opposite to EGFR-positive melanomas,
which are highly responsive to the combined treatment of
EGFR inhibitors and arsenite, as was shown in this study.
This discrepancy may reflect potential mutations and
alterations of the EGFR gene in prostate cancer cell lines,
as has been recently reported in non-small-cell lung cancer
cells (Lynch et al., 2004; Paez et al., 2004).
Materials and methods
Materials
Sodium arsenite, herbimycin and rapamycin were obtained
from Sigma (St Louis, MO, USA), pharmacological inhibitors
AG1478, LY294002, PD98059, PD153035, SB203580 and
U0126 were obtained from Calbiochem (La Jolla, CA, USA)
and SP600125 was purchased from Biomol (Plymouth Meet-
ing, PA, USA). Caspase inhibitors zVAD-fmk, Ac-IETD-
CHO (an inhibitor of caspase-8 and -6) and Ac-LEHD-CHO
(an inhibitor of caspase-9) were purchased from Calbiochem
(La Jolla, CA, USA). Precast SDS–polyacrylamide gels were
purchased from BioRad (Hercules, CA, USA).
Cell lines
Human melanoma cell lines, WM35, SBcl2, LU1205 (also
known as 1205lu), WM9, WM793 (Satyamoorthy et al., 1997;
Berking et al., 2001; Li et al., 2001, 2003) and OM431 were
maintained in DMEM medium supplemented with 10% fetal
bovine serum, L-glutamine and antibiotics. FEMX, HHMSX
and LOX, human melanoma lines (Myklebust et al., 1994),
were maintained in RPMI1640 medium supplemented with
10% fetal bovine serum, and antibiotics. Normal human
melanocytes were maintained in TICVA medium.
Treatment, apoptosis studies and fluorescence-activated cell
sorter (FACS) analysis
Cells were exposed to arsenite (1–10 mM) in the medium for 6–
48 h. Specific inhibitors of EGFR AG1478 (20 mM) and
PD153035 (20 mM), PI3K-AKT LY294002 (50 mM), of MEK-
ERK PD98059 (50 mM) or U0126 (10 mM), of JNK’s SP600125
(10–20 mM) and of MAPK p38 SB203580 (5–10mM) were used
with or without 5–10 mM arsenite. Inhibitors were added to
media 30min before arsenite treatment. Antibodies against
TNFa (BD Pharmingen, San Diego, CA, USA) and TRAIL
(Alexis, San Diego, CA, USA) were added (1–5mg/ml) 1 h
before arsenite treatment. Apoptosis was assessed by quantify-
ing the percentage of hypodiploid nuclei undergoing DNA
fragmentation (Nicoletti et al., 1991) or by quantifying the
percentage of Annexin-V–FITC-positive cells (BD Pharmin-
gen, San Diego, CA, USA). Flow cytometric analysis was
performed on a FACS Calibur flow cytometer (Becton
Dickinson) using the CellQuest program. Surface expression
of EGFR on cancer cells was determined by staining them with
phycoerythrin (PE)-anti-EGFR monoclonal antibody (BD
Pharmingen) and by flow cytometry.
Western blot analysis
Cell lysates (50–100 mg protein) were resolved on 10% SDS–
PAGE, and processed according to the standard protocols.
The antibodies used were polyclonal anti-phospho-p44/42
MAP kinase (Thr202/Tyr204), anti-p44/42 MAP kinase,
anti-phospho-AKT (Ser473), anti-AKT, anti-phospho-p38
MAP kinase (Thr180/Tyr182), anti-p38 MAP kinase, anti-
PARP (Cell Signaling, Beverly, MA, USA), polyclonal
anti-HO-1 (Stressgen, Victoria, Canada) and monoclonal
anti-b-actin (Sigma) (optimal dilutions of Abs were 1 : 1000
to 1 : 10 000). The secondary Abs (anti-rabbit or anti-mouse)
were conjugated with horseradish peroxidase (dilution 1 : 5000
to 1 : 10000). Signals were detected using the ECL system
(Amersham, Piscataway, NJ, USA).
EMSA
EMSA was performed for detection of NF-kB DNA-binding
activity, as previously described (Ivanov et al., 1994) using the
labeled double-strand oligonucleotide AGCTTGGGGAC
TTTCCAGCCG (binding sites are underlined).
Transfection and luciferase assay
The NF-kB luciferase reporter containing two kB binding sites
was used for the determination NF-kB transactivation.
Transient transfection of NF-kB reporter construct (0.5 mg)
and pCMV-b-gal (0.25 mg) into 5 105 melanoma cells was
performed using Lipofectamine (Life Technologies-Invitro-
gen). Proteins were prepared for b-gal and Luciferase analysis
16 h after transfection. Luciferase activity was determined
using the Luciferase assay system (Promega, Madison, WI,




hyde); AP-1, activator protein-1; ATF2, activating transcrip-
tion factor 2; EGFR, epidermal growth factor receptor;
EMSA, electrophoretic mobility shift assay; ERK, extracel-
lular signal-regulated kinase; FACS, fluorescence-activated cell
sorter; HO-1, heme oxygenase-1; JNK, Jun N-terminal kinase;
IkB, inhibitor of NF-kB; IKK, inhibitor nuclear factor kappa
B kinase; MAPK, mitogen-activated protein kinase; MEK,
MAPK kinase; MFI, medium fluorescence intensity; mTOR,
mammalian target of rapamycin; NF-kB, nuclear factor kappa
B; PARP, poly (ADP-ribose) polymerase; PI, propidium
iodide; PP IX (Zn2þ), Zn-containing protoporphyrin IX;
ROS, reactive oxygen species; TNFa, tumor necrosis factor
alpha; TNFR, tumor necrosis factor receptor; TRAIL, TNF-
related apoptosis-inducing ligand.
EGFR inhibitors and arsenite upregulated apoptosis




This work was supported by NIH Grant ES 11804, ES 05786
Superfund Grant P42 ES 10349 and Environmental Center Grant
P30 ES 09089. We thank Drs M Herlyn, O Fodstad, R Halaban
and Z Ronai for the cell lines; Dr A Chan, Dr S Fuchs, Ms S
Baker and Mr JA Gillespie for critical reading of the manuscript.
References
Alam J and Cook JL. (2003). Curr. Pharm. Des., 9, 2499–2511.
Alam J and Den Z. (1992). J. Biol. Chem., 267, 21894–21900.
Amit S and Ben-Neriah Y. (2003). Semin. Cancer Biol., 13,
15–28.
Berking C, Takemoto R, Schaider H, Showe L, Satyamoorthy
K, Robbins P and Herlyn M. (2001). Cancer Res., 61,
8306–8316.
Bjornsti MA and Houghton PJ. (2004). Nat. Rev. Cancer, 4,
335–348.
Blackledge G and Averbuch S. (2004). Br. J. Cancer, 90,
566–572.
Bode AM and Dong Z. (2002). Crit. Rev. Oncol. Hematol., 42,
5–24.
Brouard S, Berberat PO, Tobiasch E, Seldon MP, Bach FH
and Soares MP. (2002). J. Biol. Chem., 277, 17950–17961.
Cavigelli M, Li WW, Lin A, Su B, Yoshioka K and Karin M.
(1996). EMBO J., 15, 6269–6279.
Chen LF and Greene WC. (2004). Nat. Rev. Mol. Cell. Biol., 5,
392–401.
Chen W, Martindale JL, Holbrook NJ and Liu Y. (1998). Mol.
Cell. Biol., 18, 5178–5188.
Chen X, Thakkar H, Tyan F, Gim S, Robinson H, Lee C,
Pandey SK, Nwokorie C, Onwudiwe N and Srivastava RK.
(2001). Oncogene, 20, 6073–6083.
Cheng HY, Li P, David M, Smithgall TE, Feng L and
Lieberman MW. (2004). Oncogene, 23, 3603–3612.
Dancey J and Sausville EA. (2003). Nat. Rev. Drug Discov., 2,
296–313.
Dancey JE. (2004). Cancer Cell, 5, 411–415.
Darnell Jr JE. (2002). Nat. Rev. Cancer, 2, 740–749.
Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S,
Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis
N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R,
Hughes J, Kosmidou V, Menzies A, Mould C, Parker A,
Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H,
Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-
Jones K, Maitland N, Chenevix-Trench G, Riggins GJ,
Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A,
Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF,
Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster
R, Stratton MR and Futreal PA. (2002). Nature, 417,
949–954.
Dong J, Phelps RG, Qiao R, Yao S, Benard O, Ronai Z and
Aaronson SA. (2003). Cancer Res., 63, 3883–3885.
Durante W. (2003). J. Cell. Physiol., 195, 373–382.
Evan GI and Vousden KH. (2001). Nature, 411, 342–348.
Franco AV, Zhang XD, Van Berkel E, Sanders JE, Zhang XY,
Thomas WD, Nguyen T and Hersey P. (2001). J. Immunol.,
166, 5337–5345.
Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R,
Miller V, Natale RB, Schiller JH, Von Pawel J, Pluzanska A,
Gatzemeier U, Grous J, Ochs JS, Averbuch SD, Wolf MK,
Rennie P, Fandi A and Johnson DH. (2004). J. Clin. Oncol.,
22, 777–784.
Gong P, Stewart D, Hu B, Vinson C and Alam J. (2002). Arch.
Biochem. Biophys., 405, 265–274.
Griffith TS, Chin WA, Jackson GC, Lynch DH and Kubin
MZ. (1998). J. Immunol., 161, 2833–2840.
Gschwind A, Fischer OM and Ullrich A. (2004). Nat. Rev.
Cancer, 4, 361–370.
Halaban R. (1996). Semin. Oncol., 23, 673–681.
Hanada M, Feng J and Hemmings BA. (2004). Biochim.
Biophys. Acta, 1697, 3–16.
Hayashi T, Hideshima T and Anderson KC. (2003). Br. J.
Haematol., 120, 10–17.
Hei TK, Liu SX and Waldren C. (1998). Proc. Natl. Acad. Sci.
USA, 95, 8103–8107.
Hershko DD, Robb BW, Hungness ES, Luo G and Hasselgren
PO. (2002). J. Cell. Biochem., 84, 687–698.
Huerta-Yepez S, Vega M, Jazirehi A, Garban H, Hongo F,
Cheng G and Bonavida B. (2004). Oncogene, 23, 4993–5003.
Ivanov V, Fleming TJ and Malek TR. (1994). J. Immunol.,
153, 2394–2406.
Ivanov VN and Hei TK. (2004). J. Biol. Chem., 279,
22747–22758.
Ivanov VN and Ronai Z. (1999). J. Biol. Chem., 274,
14079–14089.
Ivanov VN, Krasilnikov M and Ronai Z. (2002). J. Biol.
Chem., 277, 4932–4944.
Jiang BH, Jiang G, Zheng JZ, Lu Z, Hunter T and Vogt PK.
(2001). Cell Growth Differ., 12, 363–369.
Johnstone RW, Ruefli AA and Lowe SW. (2002). Cell, 108,
153–164.
Kandel ES and Hay N. (1999). Exp. Cell Res., 253, 210–229.
Kapahi P, Takahashi T, Natoli G, Adams SR, Chen Y,
Tsien RY and Karin M. (2000). J. Biol. Chem., 275,
36062–36066.
Karin M, Cao Y, Greten FR and Li ZW. (2002). Nat. Rev.
Cancer, 2, 301–310.
Karin M and Lin A. (2002). Nat. Immunol., 3, 221–227.
Karin M, Yamamoto Y and Wang QM. (2004). Nat. Rev.
Drug Discov., 3, 17–26.
Kitada S, Pedersen IM, Schimmer AD and Reed JC. (2002).
Oncogene, 21, 3459–3474.
Krasilnikov M, Ivanov VN, Dong J and Ronai Z. (2003).
Oncogene, 22, 4092–4101.
Lazar-Molnar E, Hegyesi H, Toth S and Falus A. (2000).
Cytokine, 12, 547–554.
Lee PJ, Camhi SL, Chin BY, Alam J and Choi AM. (2000).
Am. J. Physiol. Lung Cell. Mol. Physiol., 279, L175–82.
Lee PJ, Jiang BH, Chin BY, Iyer NV, Alam J, Semenza GL
and Choi AM. (1997). J. Biol. Chem., 272, 5375–5381.
Levitzki A and Gazit A. (1995). Science, 267, 1782–1788.
Levy DE and Darnell Jr JE. (2002). Nat. Rev. Mol. Cell. Biol.,
3, 651–662.
Li G, Kalabis J, Xu X, Meier F, Oka M, Bogenrieder T and
Herlyn M. (2003). Oncogene, 22, 6891–6899.
Li G, Satyamoorthy K and Herlyn M. (2001). Cancer Res., 61,
3819–3825.
Li M, Cai JF and Chiu JF. (2002). J. Cell. Biochem., 87, 29–38.
Lin A and Karin M. (2003). Semin. Cancer Biol., 13, 107–114.
Liu J, Kadiiska MB, Liu Y, Lu T, Qu W and Waalkes MP.
(2001a). Toxicol. Sci., 61, 314–320.
Liu SX, Athar M, Lippai I, Waldren C and Hei TK. (2001b).
Proc. Natl. Acad. Sci. USA, 98, 1643–1648.
Ludwig S, Hoffmeyer A, Goebeler M, Kilian K, Hafner H,
Neufeld B, Han J and Rapp UR. (1998). J. Biol. Chem., 273,
1917–1922.
Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto
RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG,
EGFR inhibitors and arsenite upregulated apoptosis
VN Ivanov and TK Hei
625
Oncogene
Haluska FG, Louis DN, Christiani DC, Settleman J and
Haber DA. (2004). N. Engl. J. Med., 350, 2129–2139.
Martin D, Rojo AI, Salinas M, Diaz R, Gallardo G, Alam J,
De Galarreta CM and Cuadrado A. (2004). J. Biol. Chem.,
279, 8919–8929.
Mathas S, Lietz A, Janz M, Hinz M, Jundt F, Scheidereit C,
Bommert K and Dorken B. (2003). Blood, 102, 1028–1034.
Myklebust AT, Helseth A, Breistol K, Hall WA and Fodstad
O. (1994). J. Neurooncol., 21, 215–224.
Nicoletti I, Migliorati G, Pagliacci MC, Grignani F and
Riccardi C. (1991). J. Immunol. Methods, 139, 271–279.
Orlowski RZ and Baldwin Jr AS. (2002). Trends Mol. Med., 8,
385–389.
Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S,
Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K,
Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE and
Meyerson M. (2004). Science, 304, 1497–1500.
Perlis C and Herlyn M. (2004). Oncologist, 9, 182–187.
Rea MA, Gregg JP, Qin Q, Phillips MA and Rice RH. (2003).
Carcinogenesis, 24, 747–756.
Reifenberger J, Knobbe CB, Sterzinger AA, Blaschke B,
Schulte KW, Ruzicka T and Reifenberger G. (2004). Int. J.
Cancer, 109, 377–384.
Roussel RR and Barchowsky A. (2000). Arch. Biochem.
Biophys., 377, 204–212.
Satyamoorthy K, DeJesus E, Linnenbach AJ, Kraj B,
Kornreich DL, Rendle S, Elder DE and Herlyn M. (1997).
Melanoma Res., 7 (Suppl 2), S35–42.
Satyamoorthy K, Li G, Gerrero MR, Brose MS, Volpe P,
Weber BL, Van Belle P, Elder DE and Herlyn M. (2003).
Cancer Res., 63, 756–759.
Schlessinger J. (2000). Cell, 103, 211–225.
Shaulian E and Karin M. (2002). Nat. Cell Biol., 4, E131–E136.
Sibilia M, Fleischmann A, Behrens A, Stingl L, Carroll J, Watt
FM, Schlessinger J andWagner EF. (2000). Cell, 102, 211–220.
Snow ET. (1992). Pharmacol. Ther., 53, 31–65.
Threadgill DW, Dlugosz AA, Hansen LA, Tennenbaum T,
Lichti U, Yee D, LaMantia C, Mourton T, Herrup K,
Harris RC, Barnard JA, Yuspa SH, Coffey RJ and
Magnuson T. (1995). Science, 269, 230–234.
Tuveson DA, Weber BL and Herlyn M. (2003). Cancer Cell, 4,
95–98.
von Willebrand M, Zacksenhaus E, Cheng E, Glazer P and
Halaban R. (2003). Cancer Res., 63, 1420–1429.
Wakeling AE, Barker AJ, Davies DH, Brown DS, Green LR,
Cartlidge SA and Woodburn JR. (1996). Breast Cancer Res.
Treat., 38, 67–73.
Yarden Y and Sliwkowski MX. (2001). Nat. Rev. Mol. Cell.
Biol., 2, 127–137.
Yih LH, Peck K and Lee TC. (2002). Carcinogenesis, 23, 867–876.
Zhang X, Shan P, Alam J, Davis RJ, Flavell RA and Lee PJ.
(2003a). J. Biol. Chem., 278, 22061–22070.
Zhang XD, Borrow JM, Zhang XY, Nguyen T and Hersey P.
(2003b). Oncogene, 22, 2869–2881.
Zheng XH, Watts GS, Vaught S and Gandolfi AJ. (2003).
Toxicology, 187, 39–48.
EGFR inhibitors and arsenite upregulated apoptosis
VN Ivanov and TK Hei
626
Oncogene
